<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BCL-2 inhibitor safety** &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/bcl-2-inhibitor-safety/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 25 Jan 2026 19:40:25 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>BCL-2 inhibitor safety** &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Assessing Venetoclax’s Toxicity vs. Efficacy in Patients</title>
		<link>https://bioengineer.org/assessing-venetoclaxs-toxicity-vs-efficacy-in-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 19:39:56 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[BCL-2 inhibitor safety**]]></category>
		<category><![CDATA[gerçek dünya verisi]]></category>
		<category><![CDATA[hematologic malignancy treatment]]></category>
		<category><![CDATA[hematolojik kanserler) odaklanarak en uygun 5 etiket: **venetoclax toxicity-efficacy balance]]></category>
		<category><![CDATA[Hematolojik Maligniteler]]></category>
		<category><![CDATA[İçeriğin ana temalarına (venetoklaks]]></category>
		<category><![CDATA[Kişiselleştirilmiş tedavi]]></category>
		<category><![CDATA[Kişiselleştirilmiş Tedavi** **Açıklama:** 1. **Venetoclax:** Çalışmanın ana konusu olan ilaç. 2. **Tok]]></category>
		<category><![CDATA[Makale içeriğine göre en uygun 5 etiket: **Venetoclax]]></category>
		<category><![CDATA[personalized cancer therapy]]></category>
		<category><![CDATA[real-world oncology data]]></category>
		<category><![CDATA[Toksisite-Etkinlik Dengesi]]></category>
		<guid isPermaLink="false">https://bioengineer.org/assessing-venetoclaxs-toxicity-vs-efficacy-in-patients/</guid>

					<description><![CDATA[In a groundbreaking study published in the esteemed journal “Annals of Hematology,” researchers led by Laura Osanno, along with her colleagues, delve into the complex interplay between efficacy and toxicity in the use of venetoclax—a targeted therapy that has revolutionized the treatment landscape for certain hematological malignancies. The study titled “Predicting the toxicity-efficacy ratio of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320792</post-id>	</item>
	</channel>
</rss>
